{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:29:45Z","timestamp":1786346985775,"version":"build-2736575974"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100008089","name":"Fondazione Internazionale Menarini","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13300-026-01889-x","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:34:20Z","timestamp":1783931660000},"page":"1095-1117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementing SGLT2 Inhibitor Therapy in Line with the New NICE Guidelines for Type 2 Diabetes Management"],"prefix":"10.1007","volume":"17","author":[{"given":"Philip","family":"Newland-Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Diggle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Kanumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Seidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adie","family":"Viljoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-8404","authenticated-orcid":false,"given":"John P. H.","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"1889_CR1","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s13300-018-0471-8","volume":"9","author":"J Wilding","year":"2018","unstructured":"Wilding J, Fernando K, Milne N, Evans M, Ali A, Bain S, et\u00a0al. SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice. Diabetes Ther. 2018;9:1757\u201373. https:\/\/doi.org\/10.1007\/s13300-018-0471-8.","journal-title":"Diabetes Ther"},{"key":"1889_CR2","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s13300-019-0657-8","volume":"10","author":"A Ali","year":"2019","unstructured":"Ali A, Bain S, Hicks D, Newland Jones P, Patel DC, Evans M, et\u00a0al. SGLT2 inhibitors: cardiovascular benefits beyond HbA1c-translating evidence into practice. Diabetes Ther. 2019;10:1595\u2013622. https:\/\/doi.org\/10.1007\/s13300-019-0657-8.","journal-title":"Diabetes Ther"},{"key":"1889_CR3","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s13300-020-00930-x","volume":"11","author":"DC Wheeler","year":"2020","unstructured":"Wheeler DC, James J, Patel D, Viljoen A, Ali A, Evans M, et\u00a0al. SGLT2 inhibitors: slowing of chronic kidney disease progression in type 2 diabetes. Diabetes Ther. 2020;11:2757\u201374. https:\/\/doi.org\/10.1007\/s13300-020-00930-x.","journal-title":"Diabetes Ther"},{"key":"1889_CR4","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s13300-022-01228-w","volume":"13","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Evans M, Fernando K, Gorriz JL, Cebrian A, Diggle J, et\u00a0al. The place and value of sodium-glucose cotransporter 2 inhibitors in the evolving treatment paradigm for type 2 diabetes mellitus: a narrative review. Diabetes Ther. 2022;13:847\u201372. https:\/\/doi.org\/10.1007\/s13300-022-01228-w.","journal-title":"Diabetes Ther"},{"key":"1889_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13300-024-01550-5","volume":"15","author":"S Seidu","year":"2024","unstructured":"Seidu S, Alabraba V, Davies S, Newland-Jones P, Fernando K, Bain SC, et\u00a0al. SGLT2 inhibitors \u2013 The new standard of care for cardiovascular, renal and metabolic protection in type 2 diabetes: a narrative review. Diabetes Ther. 2024;15:1099\u2013124. https:\/\/doi.org\/10.1007\/s13300-024-01550-5.","journal-title":"Diabetes Ther"},{"key":"1889_CR6","unstructured":"National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline. NG28 [Internet]. 2026 [cited 18 Feb 2026]. https:\/\/www.nice.org.uk\/guidance\/ng28. Accessed 18 Feb 2026"},{"key":"1889_CR7","first-page":"5","volume":"28","author":"P Brown","year":"2026","unstructured":"Brown P, Diggle J. At a glance factsheet: the NICE NG28 type 2 diabetes guideline: management update \u2013 What\u2019s new? Diabetes Prim Care. 2026;28:5\u20138.","journal-title":"Diabetes Prim Care"},{"key":"1889_CR8","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/dom.14671","volume":"24","author":"JY Barraclough","year":"2022","unstructured":"Barraclough JY, Yu J, Figtree GA, Perkovic V, Heerspink HJL, Neuen BL, et\u00a0al. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: data from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. 2022;24:1072\u201383. https:\/\/doi.org\/10.1111\/dom.14671.","journal-title":"Diabetes Obes Metab"},{"key":"1889_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et\u00a0al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X.","journal-title":"Lancet"},{"key":"1889_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et\u00a0al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1515920.","journal-title":"N Engl J Med"},{"key":"1889_CR11","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et\u00a0al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"key":"1889_CR12","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, et\u00a0al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE\u2013TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606\u201317. https:\/\/doi.org\/10.1016\/S2213-8587(19)30180-9.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1889_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et\u00a0al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"key":"1889_CR14","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et\u00a0al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","journal-title":"N Engl J Med"},{"key":"1889_CR15","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et\u00a0al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"key":"1889_CR16","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","volume":"42","author":"BL Neuen","year":"2021","unstructured":"Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, et\u00a0al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021;42:4891\u2013901. https:\/\/doi.org\/10.1093\/eurheartj\/ehab497.","journal-title":"Eur Heart J"},{"key":"1889_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et\u00a0al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136:249\u201359. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.029190.","journal-title":"Circulation"},{"key":"1889_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","volume":"8","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, et\u00a0al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8:27\u201335. https:\/\/doi.org\/10.1016\/S2213-8587(19)30384-5.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1889_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12933-021-01345-z","volume":"20","author":"K Khunti","year":"2021","unstructured":"Khunti K, Kosiborod M, Kim DJ, Kohsaka S, Lam CSP, Goh S-Y, et\u00a0al. Cardiovascular outcomes with sodium\u2013glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovasc Diabetol. 2021;20:159. https:\/\/doi.org\/10.1186\/s12933-021-01345-z.","journal-title":"Cardiovasc Diabetol"},{"key":"1889_CR20","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et\u00a0al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2004967.","journal-title":"N Engl J Med"},{"key":"1889_CR21","unstructured":"A. Menarini Farmaceutica Internazionale SRL. Invokana 300 mg film-coated tablets. Summary of product characteristics [Internet]. 2025 [cited 27 March 2026]. https:\/\/www.medicines.org.uk\/emc\/product\/11409. Accessed 27 Mar 2026"},{"key":"1889_CR22","unstructured":"AstraZeneca UK Limited. Forxiga 10 mg film-coated tablets. Summary of product characteristics [Internet]. 2024 [cited 27 March 2026]. https:\/\/www.medicines.org.uk\/emc\/product\/7607\/smpc. Accessed 27 Mar 2026"},{"key":"1889_CR23","unstructured":"Merck Sharp & Dohme (UK) Limited. Steglatro 15 mg film-coated tablets. Summary of product characteristics [Internet]. 2025 [cited 27 March 2026]. https:\/\/www.medicines.org.uk\/emc\/product\/10099\/smpc. Accessed 27 Mar 2026"},{"key":"1889_CR24","unstructured":"Boehringer Ingelheim Limited. Jardiance 25 mg film-coated tablets. Summary of product characteristics [Internet]. 2025 [cited 27 March 2026]. https:\/\/www.medicines.org.uk\/emc\/product\/7703\/smpc. Accessed 27 Mar 2026"},{"key":"1889_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01530-9","author":"P Rodriguez","year":"2024","unstructured":"Rodriguez P, San Martin VT, Pantalone KM. Therapeutic inertia in the management of type 2 diabetes: a narrative review. Diabetes Ther. 2024. https:\/\/doi.org\/10.1007\/s13300-024-01530-9. (Adis;).","journal-title":"Diabetes Ther"},{"key":"1889_CR26","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1007\/s00125-025-06439-x","volume":"68","author":"C-E Lim","year":"2025","unstructured":"Lim C-E, Pasternak B, Eliasson B, Ueda P. Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes. Diabetologia. 2025;68:1680\u201395. https:\/\/doi.org\/10.1007\/s00125-025-06439-x.","journal-title":"Diabetologia"},{"key":"1889_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59010182","volume":"59","author":"TH Almigbal","year":"2023","unstructured":"Almigbal TH, Alzarah SA, Aljanoubi FA, Alhafez NA, Aldawsari MR, Alghadeer ZY, et\u00a0al. Clinical inertia in the management of type 2 diabetes mellitus: a systematic review. Medicina (Kaunas). 2023;59:010182. https:\/\/doi.org\/10.3390\/medicina59010182.","journal-title":"Medicina (Kaunas)"},{"key":"1889_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107813","volume":"35","author":"N Kanumilli","year":"2021","unstructured":"Kanumilli N, Brunton S, Cos X, Deed G, Kushner P, Lin P, et\u00a0al. Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management. J Diabetes Complications. 2021;35:107813. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107813.","journal-title":"J Diabetes Complications"},{"key":"1889_CR29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.diabet.2017.06.003","volume":"43","author":"G Reach","year":"2017","unstructured":"Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43:501\u201311. https:\/\/doi.org\/10.1016\/j.diabet.2017.06.003.","journal-title":"Diabetes Metab"},{"key":"1889_CR30","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2337\/dc17-1144","volume":"42","author":"N Laiteerapong","year":"2019","unstructured":"Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et\u00a0al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2019;42:416\u201326. https:\/\/doi.org\/10.2337\/dc17-1144.","journal-title":"Diabetes Care"},{"key":"1889_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","volume":"404","author":"AI Adler","year":"2024","unstructured":"Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024;404:145\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(24)00537-3.","journal-title":"Lancet"},{"key":"1889_CR32","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/dom.15040","volume":"25","author":"P McEwan","year":"2023","unstructured":"McEwan P, Foos V, Martin B, Chen J, Evans M. Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidence. Diabetes Obes Metab. 2023;25:1830\u20138. https:\/\/doi.org\/10.1111\/dom.15040.","journal-title":"Diabetes Obes Metab"},{"key":"1889_CR33","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et\u00a0al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925\u201366. https:\/\/doi.org\/10.1007\/s00125-022-05787-2.","journal-title":"Diabetologia"},{"key":"1889_CR34","unstructured":"ClinRisk Ltd. QRISK\u00ae3-lifetime cardiovascular risk calculator [Internet]. 2023 [cited 27 March 2026]. https:\/\/qrisk.org\/lifetime. Accessed 27 Mar 2026"},{"key":"1889_CR35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/00325481.2016.1169894","volume":"128","author":"L Blonde","year":"2016","unstructured":"Blonde L, Stenl\u00f6f K, Fung A, Xie J, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016;128:371\u201380. https:\/\/doi.org\/10.1080\/00325481.2016.1169894.","journal-title":"Postgrad Med"},{"key":"1889_CR36","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/dom.12670","volume":"18","author":"F Zaccardi","year":"2016","unstructured":"Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783\u201394. https:\/\/doi.org\/10.1111\/dom.12670.","journal-title":"Diabetes Obes Metab"},{"key":"1889_CR37","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2025.12658","author":"Z Zhan","year":"2025","unstructured":"Zhan Z, Wang J, Shen N, Liu X, Wang L. Effectiveness of SGLT2 inhibitors compared to sulphonylureas for long-term glycemic control in type 2 diabetes: a meta-analysis. Biomol Biomed. 2025. https:\/\/doi.org\/10.17305\/bb.2025.12658.","journal-title":"Biomol Biomed"},{"key":"1889_CR38","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren \u00d6, Kullberg J, Johansson L, Wilding J, Langkilde AM, et\u00a0al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020\u201331. https:\/\/doi.org\/10.1210\/jc.2011-2260.","journal-title":"J Clin Endocrinol Metab"},{"key":"1889_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-088687","volume":"15","author":"L Xu","year":"2025","unstructured":"Xu L, Wu Y, Li J, Ding Y, Chow J, Li L, et\u00a0al. Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis. BMJ Open. 2025;15:e088687. https:\/\/doi.org\/10.1136\/bmjopen-2024-088687.","journal-title":"BMJ Open"},{"key":"1889_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134248","volume":"12","author":"JJ Gorgojo-Martinez","year":"2023","unstructured":"Gorgojo-Martinez JJ, Ferreira-Ocampo PJ, Gald\u00f3n Sanz-Pastor A, C\u00e1rdenas-Salas J, Ant\u00f3n-Bravo T, Brito-Sanfiel M, et\u00a0al. Effectiveness and tolerability of the intensification of canagliflozin dose from 100 mg to 300 mg daily in patients with type 2 diabetes in real life: The INTENSIFY study. J Clin Med. 2023;12:134248. https:\/\/doi.org\/10.3390\/jcm12134248.","journal-title":"J Clin Med"},{"key":"1889_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072275","volume":"9","author":"JJ Gorgojo-Mart\u00ednez","year":"2020","unstructured":"Gorgojo-Mart\u00ednez JJ, Gargallo-Fern\u00e1ndez MA, Gald\u00f3n Sanz-Pastor A, Ant\u00f3n-Bravo T, Brito-Sanfiel M, Wong-Cruz J. Real-world clinical outcomes associated with canagliflozin in patients with type 2 diabetes mellitus in Spain: the Real-Wecan study. J Clin Med. 2020;9:2275. https:\/\/doi.org\/10.3390\/jcm9072275.","journal-title":"J Clin Med"},{"key":"1889_CR42","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1111\/dom.14143","volume":"22","author":"DR Matthews","year":"2020","unstructured":"Matthews DR, Wysham C, Davies M, Slee A, Alba M, Lee M, et\u00a0al. Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS program. Diabetes Obes Metab. 2020;22:2199\u2013203. https:\/\/doi.org\/10.1111\/dom.14143.","journal-title":"Diabetes Obes Metab"},{"key":"1889_CR43","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1093\/ndt\/gfaf044","volume":"40","author":"B Beal","year":"2025","unstructured":"Beal B, Buizen L, Yeung EK, Heath L, Houston L, Cherney DZI, et\u00a0al. Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial. Nephrol Dial Transplant. 2025;40:1727\u201335. https:\/\/doi.org\/10.1093\/ndt\/gfaf044.","journal-title":"Nephrol Dial Transplant"},{"key":"1889_CR44","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1111\/dom.16188","volume":"27","author":"R Suzuki","year":"2025","unstructured":"Suzuki R, Shoji S, Yoshinaga Y, Kosakai Y, Shintani-Tachi M. Risk of insulin initiation with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: a real-world claims database study in Japan. Diabetes Obes Metab. 2025;27:1960\u201371. https:\/\/doi.org\/10.1111\/dom.16188.","journal-title":"Diabetes Obes Metab"},{"key":"1889_CR45","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102:S1-127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","journal-title":"Kidney Int"},{"key":"1889_CR46","unstructured":"UK Kidney Association. UK Kidney Association clinical practice guideline: Sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease [Internet]. 2021 [cited 27 March 2026]. https:\/\/ukkidney.org\/health-professionals\/guidelines\/ukka-clinical-practice-guideline-sodium-glucose-co-transporter-2. Accessed 27 Mar 2026"},{"key":"1889_CR47","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et\u00a0al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043\u2013140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192.","journal-title":"Eur Heart J"},{"key":"1889_CR48","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1002\/ehf2.13236","volume":"8","author":"J Yu","year":"2021","unstructured":"Yu J, Arnott C, Neuen BL, Heersprink HL, Mahaffey KW, Cannon CP, et\u00a0al. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS program. ESC Heart Fail. 2021;8:1482\u201393. https:\/\/doi.org\/10.1002\/ehf2.13236.","journal-title":"ESC Heart Fail"},{"key":"1889_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000503919","volume":"10","author":"KB Lo","year":"2020","unstructured":"Lo KB, Gul F, Ram P, Kluger AY, Tecson KM, McCullough PA, et\u00a0al. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Med. 2020;10:1\u201310. https:\/\/doi.org\/10.1159\/000503919.","journal-title":"Cardiorenal Med"},{"key":"1889_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"key":"1889_CR51","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et\u00a0al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"key":"1889_CR52","unstructured":"Brown P. Need to know guide: SGLT2 inhibitor indications, doses and licences (updated 2023). Diabetes & Primary Care [Internet]. 2023 [cited 27 March 2026];25:9\u201310. https:\/\/diabetesonthenet.com\/wp-content\/uploads\/9-10.-SGLT2i-N2K-2023-update.pdf. Accessed 27 Mar 2026"},{"key":"1889_CR53","unstructured":"National Institute for Health and Care Excellence. Biggest shake-up in type 2 diabetes care in a decade announced [Internet]. 2025 [cited 27 March 2026]. https:\/\/www.nice.org.uk\/news\/articles\/biggest-shake-up-in-type-2-diabetes-care-in-a-decade-announced. Accessed 27 Mar 2026"},{"key":"1889_CR54","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"NA ElSayed","year":"2025","unstructured":"ElSayed NA, McCoy RG, Aleppo G, Bajaj M, Balapattabi K, Beverly EA, et\u00a0al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025. Diabetes Care. 2025;48:S181-206. https:\/\/doi.org\/10.2337\/dc25-S009.","journal-title":"Diabetes Care"},{"key":"1889_CR55","unstructured":"National Institute for Health and Care Excellence. Clinical knowledge summary: diabetes - Type 2: SGLT-2 inhibitors [Internet]. 2025 [cited 27 March 2026]. https:\/\/cks.nice.org.uk\/topics\/diabetes-type-2\/prescribing-information\/sglt-2-inhibitors\/. Accessed 27 Mar 2026"},{"key":"1889_CR56","unstructured":"National Institute for Health and Care Excellence. Putting NICE guidance in to practice. Resource impact report: type 2 diabetes in adults: management (update) [Internet]. 2022 [cited 27 March 2026]. https:\/\/www.nice.org.uk\/guidance\/ng28\/resources\/resource-impact-report-type-2-diabetes-and-cardiovascular-risk-update-pdf-10958006557. Accessed 27 Mar 2026"},{"key":"1889_CR57","unstructured":"National Institute for Health and Care Excellence. Epidemiological report. Uptake of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a report for NICE committee members [Internet]. 2024 [cited 27 March 2026]. https:\/\/www.nice.org.uk\/guidance\/gid-ng10336\/documents\/addendum-appendix. Accessed 27 Mar 2026"},{"key":"1889_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-020-1292-5","volume":"20","author":"Y Yoshida","year":"2020","unstructured":"Yoshida Y, Cheng X, Shao H, Fonseca VA, Shi L. A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes. Curr Diab Rep. 2020;20:12. https:\/\/doi.org\/10.1007\/s11892-020-1292-5.","journal-title":"Curr Diab Rep"},{"key":"1889_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40191-8","volume":"9","author":"KL Chin","year":"2019","unstructured":"Chin KL, Ofori-Asenso R, Si S, Hird TR, Magliano DJ, Zoungas S, et\u00a0al. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes. Sci Rep. 2019;9:3256. https:\/\/doi.org\/10.1038\/s41598-019-40191-8.","journal-title":"Sci Rep"},{"key":"1889_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-054654","volume":"12","author":"S Hodgson","year":"2022","unstructured":"Hodgson S, Morgan-Harrisskitt J, Hounkpatin H, Stuart B, Dambha-Miller H. Primary care service utilisation and outcomes in type 2 diabetes: a longitudinal cohort analysis. BMJ Open. 2022;12:e054654. https:\/\/doi.org\/10.1136\/bmjopen-2021-054654.","journal-title":"BMJ Open"},{"key":"1889_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1373-y","volume":"17","author":"M Nowakowska","year":"2019","unstructured":"Nowakowska M, Zghebi SS, Ashcroft DM, Buchan I, Chew-Graham C, Holt T, et\u00a0al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019;17:145. https:\/\/doi.org\/10.1186\/s12916-019-1373-y.","journal-title":"BMC Med"},{"key":"1889_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033866","volume":"10","author":"SS Zghebi","year":"2020","unstructured":"Zghebi SS, Steinke DT, Rutter MK, Ashcroft DM. Eleven-year multimorbidity burden among 637 255 people with and without type 2 diabetes: a population-based study using primary care and linked hospitalisation data. BMJ Open. 2020;10:e033866. https:\/\/doi.org\/10.1136\/bmjopen-2019-033866.","journal-title":"BMJ Open"},{"key":"1889_CR63","doi-asserted-by":"publisher","DOI":"10.1177\/2042018819844694","volume":"10","author":"S Khunti","year":"2019","unstructured":"Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab. 2019;10:2042018819844694. https:\/\/doi.org\/10.1177\/2042018819844694.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"1889_CR64","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.diabres.2014.05.005","volume":"105","author":"WD Strain","year":"2014","unstructured":"Strain WD, Cos X, Hirst M, Vencio S, Mohan V, Vok\u00f3 Z, et\u00a0al. Time to do more: addressing clinical inertia in the management of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2014;105:302\u201312. https:\/\/doi.org\/10.1016\/j.diabres.2014.05.005.","journal-title":"Diabetes Res Clin Pract"},{"key":"1889_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01154-w","volume":"19","author":"G Schernthaner","year":"2020","unstructured":"Schernthaner G, Shehadeh N, Ametov AS, Bazarova AV, Ebrahimi F, Fasching P, et\u00a0al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19:185. https:\/\/doi.org\/10.1186\/s12933-020-01154-w.","journal-title":"Cardiovasc Diabetol"},{"key":"1889_CR66","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3803\/EnM.2022.1649","volume":"38","author":"B-H Chew","year":"2023","unstructured":"Chew B-H, Mohd-Yusof B-N, Lai PSM, Khunti K. Overcoming therapeutic inertia as the Achilles\u2019 heel for improving suboptimal diabetes care: an integrative review. Endocrinol Metab (Seoul). 2023;38:34\u201342. https:\/\/doi.org\/10.3803\/EnM.2022.1649.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"1889_CR67","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2337\/dc19-1476","volume":"43","author":"A Cahn","year":"2020","unstructured":"Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, et\u00a0al. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE\u2013TIMI 58 study. Diabetes Care. 2020;43:468\u201375. https:\/\/doi.org\/10.2337\/dc19-1476.","journal-title":"Diabetes Care"},{"key":"1889_CR68","first-page":"113","volume":"25","author":"P Brown","year":"2023","unstructured":"Brown P. How to use SGLT2 inhibitors safely and effectively. Diabetes Prim Care. 2023;25:113\u20135.","journal-title":"Diabetes Prim Care"},{"key":"1889_CR69","first-page":"49","volume":"22","author":"J Diggle","year":"2020","unstructured":"Diggle J. Ketones and diabetes. Diabetes Prim Care. 2020;22:49\u201350.","journal-title":"Diabetes Prim Care"},{"key":"1889_CR70","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group, SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788\u2013801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8.","journal-title":"Lancet"},{"key":"1889_CR71","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1111\/dom.70728","volume":"28","author":"S Seidu","year":"2026","unstructured":"Seidu S, Kunutsor SK, Taguiam E, Khunti K. Interrelationship between baseline HbA1c, SGLT-2 inhibitor use and risk of diabetic ketoacidosis in adults with type 2 diabetes: a systematic review and meta\u2010analysis. Diabetes Obes Metab. 2026;28:5217\u201328. https:\/\/doi.org\/10.1111\/dom.70728.","journal-title":"Diabetes Obes Metab"},{"key":"1889_CR72","unstructured":"Down S. How to advise on sick day rules. 2020;22 47 48"},{"key":"1889_CR73","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1111\/dom.16498","volume":"27","author":"P Highton","year":"2025","unstructured":"Highton P, Abdala R, Evley R, Balasubramanian V, Davies M, Dhatariya K, et\u00a0al. The use of SGLT2 inhibitors in people with diabetes-related foot disease: a Delphi-based consensus study. Diabetes Obes Metab. 2025;27:4537\u201346. https:\/\/doi.org\/10.1111\/dom.16498. (John Wiley and Sons Inc;).","journal-title":"Diabetes Obes Metab"},{"key":"1889_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.deman.2022.100054","volume":"6","author":"AJ Scheen","year":"2022","unstructured":"Scheen AJ. Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: a meta-analysis of observational studies. Diabetes Epidemiol Manag. 2022;6:100054. https:\/\/doi.org\/10.1016\/j.deman.2022.100054.","journal-title":"Diabetes Epidemiol Manag"},{"key":"1889_CR75","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","volume":"183","author":"E D\u2019Andrea","year":"2023","unstructured":"D\u2019Andrea E, Wexler DJ, Kim SC, Paik JM, Alt E, Patorno E. Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels. JAMA Intern Med. 2023;183:242\u201354. https:\/\/doi.org\/10.1001\/jamainternmed.2022.6664.","journal-title":"JAMA Intern Med"},{"key":"1889_CR76","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000520903","volume":"107","author":"RM See","year":"2022","unstructured":"See RM, Teo YN, Teo YH, Syn NL, Yip ASY, Leong S, et\u00a0al. Effects of sodium-glucose cotransporter 2 on amputation events: a systematic review and meta-analysis of randomized-controlled trials. Pharmacology. 2022;107:123\u201330. https:\/\/doi.org\/10.1159\/000520903.","journal-title":"Pharmacology"},{"key":"1889_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01897-2","author":"NCC Werkman","year":"2023","unstructured":"Werkman NCC, Driessen JHM, Stehouwer CDA, Vestergaard P, Schaper NC, van den Bergh JP, et\u00a0al. The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study. Cardiovasc Diabetol. 2023. https:\/\/doi.org\/10.1186\/s12933-023-01897-2. (BioMed Central Ltd).","journal-title":"Cardiovasc Diabetol"},{"key":"1889_CR78","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1111\/dom.15091","volume":"25","author":"A Kang","year":"2023","unstructured":"Kang A, Smyth B, Neuen BL, Heerspink HJL, Di Tanna GL, Zhang H, et\u00a0al. The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: a pooled post hoc analysis from the CANVAS program and CREDENCE randomized double-blind trials. Diabetes Obes Metab. 2023;25:2151\u201362. https:\/\/doi.org\/10.1111\/dom.15091.","journal-title":"Diabetes Obes Metab"},{"key":"1889_CR79","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1681\/ASN.2016030278","volume":"28","author":"HJL Heerspink","year":"2017","unstructured":"Heerspink HJL, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28:368\u201375. https:\/\/doi.org\/10.1681\/ASN.2016030278.","journal-title":"J Am Soc Nephrol"},{"key":"1889_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216509","volume":"13","author":"JJ Gorgojo-Mart\u00ednez","year":"2024","unstructured":"Gorgojo-Mart\u00ednez JJ, G\u00f3rriz JL, Cebri\u00e1n-Cuenca A, Castro Conde A, Velasco Arribas M. Clinical recommendations for managing genitourinary adverse effects in patients treated with SGLT-2 inhibitors: a multidisciplinary expert consensus. J Clin Med. 2024;13:6509. https:\/\/doi.org\/10.3390\/jcm13216509.","journal-title":"J Clin Med"},{"key":"1889_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001238","author":"AP McGovern","year":"2020","unstructured":"McGovern AP, Hogg M, Shields BM, Sattar NA, Holman RR, Pearson ER, et\u00a0al. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. 2020. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001238.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1889_CR82","unstructured":"Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: reports of Fournier\u2019s gangrene (necrotising fasciitis of the genitalia or perineum) [Internet]. 2019 [cited 27 March 2026]. https:\/\/www.gov.uk\/drug-safety-update\/sglt2-inhibitors-reports-of-fournier-s-gangrene-necrotising-fasciitis-of-the-genitalia-or-perineum. Accessed 27 Mar 2026"},{"key":"1889_CR83","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4103\/ijem.IJEM_614_18","volume":"23","author":"AS Dass","year":"2019","unstructured":"Dass AS, Immaculate G, Bhattacharyya A. Fournier\u2019s gangrene and sodium-glucose co-transporter 2 (SGLT2) inhibitors: our experience. Indian J Endocrinol Metab. 2019;23:165\u20136. https:\/\/doi.org\/10.4103\/ijem.IJEM_614_18.","journal-title":"Indian J Endocrinol Metab"},{"key":"1889_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000985","volume":"8","author":"JY Yang","year":"2020","unstructured":"Yang JY, Wang T, Pate V, Buse JB, St\u00fcrmer T. Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier\u2019s gangrene. BMJ Open Diabetes Res Care. 2020;8:e000985. https:\/\/doi.org\/10.1136\/bmjdrc-2019-000985.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1889_CR85","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27773","volume":"14","author":"T Chowdhury","year":"2022","unstructured":"Chowdhury T, Gousy N, Bellamkonda A, Dutta J, Zaman CF, Zakia UB, et\u00a0al. Fournier\u2019s gangrene: a coexistence or consanguinity of SGLT-2 inhibitor therapy. Cureus. 2022;14:e27773. https:\/\/doi.org\/10.7759\/cureus.27773.","journal-title":"Cureus"},{"key":"1889_CR86","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4081\/aiua.2016.3.157","volume":"88","author":"A Singh","year":"2016","unstructured":"Singh A, Ahmed K, Aydin A, Khan MS, Dasgupta P. Fournier\u2019s gangrene. A clinical review. Arch Ital Urol Androl. 2016;88:157\u201364. https:\/\/doi.org\/10.4081\/aiua.2016.3.157.","journal-title":"Arch Ital Urol Androl"},{"key":"1889_CR87","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.bja.2023.12.015","volume":"132","author":"K Dhatariya","year":"2024","unstructured":"Dhatariya K, Levy N, Russon K, Patel A, Frank C, Mustafa O, et\u00a0al. Perioperative use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes mellitus. Br J Anaesth. 2024;132:639\u201343. https:\/\/doi.org\/10.1016\/j.bja.2023.12.015.","journal-title":"Br J Anaesth"},{"key":"1889_CR88","unstructured":"Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness [Internet]. 2020 [cited 27 March 2026]. https:\/\/www.gov.uk\/drug-safety-update\/sglt2-inhibitors-monitor-ketones-in-blood-during-treatment-interruption-for-surgical-procedures-or-acute-serious-medical-illness. Accessed 27 Mar 2026"},{"key":"1889_CR89","doi-asserted-by":"publisher","first-page":"958","DOI":"10.5005\/jp-journals-10071-23929","volume":"25","author":"S Vadi","year":"2021","unstructured":"Vadi S, Lad V, Kapoor D. Perioperative implication of sodium-glucose cotransporter-2 inhibitor in a patient following major surgery. Indian J Crit Care Med. 2021;25:958\u20139. https:\/\/doi.org\/10.5005\/jp-journals-10071-23929.","journal-title":"Indian J Crit Care Med"},{"key":"1889_CR90","unstructured":"Kumar S, Bhavnani SP, Goyal P, Rich MW, Krishnaswami A. Preoperative cessation of SGLT2i. American College of Cardiology [Internet]. 2022 [cited 27 March 2026]; https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2022\/10\/07\/17\/21\/Preoperative-Cessation-of-SGLT2i. Accessed 27 Mar 2026"},{"key":"1889_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100627","author":"AJ Scheen","year":"2023","unstructured":"Scheen AJ. Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation. Lancet Reg Health Eur. 2023. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100627. (Elsevier Ltd).","journal-title":"Lancet Reg Health Eur"},{"key":"1889_CR92","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1053\/jinf.2000.0723","volume":"41","author":"R Goswami","year":"2000","unstructured":"Goswami R, Dadhwal V, Tejaswi S, Datta K, Paul A, Haricharan RN, et\u00a0al. Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect. 2000;41:162\u20136.","journal-title":"J Infect"},{"key":"1889_CR93","unstructured":"Sayfi S, Malik N. Prescribing pearls: a guide to SGLT2 inhibitors. Diabetes & Primary Care. 2025;7\u201310."}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01889-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01889-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01889-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:00:54Z","timestamp":1786345254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01889-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":93,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1889"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01889-x","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Marc Evans is an editor-in-chief of\n                      Diabetes Therapy\n                      . Marc Evans was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. Philip Newland-Jones: sponsorship for education events, research undertaken for, or fees received from, educational speaking from Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Sanofi, Eli Lilly, Novo Nordisk, Menarini and Roche. Partha Kar: educational meetings: Eli Lilly, Novo Nordisk, Sanofi, Napp, Takeda, Boehringer Ingelheim, Abbott, Dexcom, Medtronic, Insulet, and AstraZeneca. Beth Kelly: no relevant conflicts of interest. Rahul Mohan: consulting fees: Abbott, Dexcom, Eli Lilly and Roche; speaking fees: Abbott, Eli Lilly, A. Menarini, Boehringer-Ingelheim and Daiichi Sankyo. Sarah Davies: funding for speaking and attending conferences: Abbott, Lily, Boehringer Ingelheim, Roche, Astra Zeneca, Mennarini, Dexcom, Daaich Sankyo and Novo Nordisk. Jane Diggle: current committee member and former co-vice chair of Primary Care Diabetes and Obesity Society; editor-in-chief of\n                      Diabetes and Primary Care\n                      journal; member of the Insights for Diabetes Excellence, Access and Learning (iDEAL) Advisory Group; tutor for iHeed Post-Graduate Diploma in Diabetes (University of Warwick); funding for educational session provision and documents, and advisory board attendance: Abbott, Bayer, AstraZeneca, Boehringer Ingelheim Eli Lilly, Menarini, Novo Nordisk, Roche, Sanofi, Sciarc GmbH, Sherborne Gibbs Limited and Tetris. Kevin Fernando: speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Daiichi Sankyo, Lilly, Menarini, Grunenthal, Boston Scientific, Sinocare and Novo Nordisk; consultancy fees from Dexcom, Boehringer Ingelheim, Lilly, Roche, Oviva, Idorsia, Grunenthal, Boston Scientific and Abbvie; conference registration and subsistence from Menarini, Bayer, Daiichi Sankyo and Lilly. Debbie Hicks: no relevant conflicts of interest. Naresh Kanumilli: current roles: PCDS trustee, DUKPCOC committee member, GM diabetes board chair, GM and EC SCN clinical lead; honorary clinical advisor for primary care  GMCRN; honoraria\/travel grants: AstraZeneca,\u00a0Boehringer Ingelheim, Lilly, MSD,\u00a0Novartis, Novo Nordisk, Roche, Sanofi and Menarini; research support: AstraZeneca,\u00a0Boehringer Ingelheim, Lilly,\u00a0MSD, Novartis, Janssen, Novo Nordisk, Roche and Sanofi; speaker\u2019s bureau: AstraZeneca, Menarini Group, Boehringer Ingelheim, Lilly, MSD,\u00a0Napp, Novartis, Novo Nordisk, Roche, Amgen and Sanofi. Nicola Milne: member of Diabetes UK Council of Health Care Professionals, co-vice chair and trustee of Primary Care Diabetes and Obesity Society; editorial board member for\n                      Journal of Diabetes Nursing\n                      and\n                      Journal of Diabetes and Primary Care\n                      ; member of Diabetes UK Research and Study Group (Group 6: Complications of Diabetes); DiaST lead (Northenden and Brooklands PCN; now CVKM lead); tutor I-Heed (Warwick University) Diabetes Diploma; work for Omniamed Publications Company:\n                      Journal of Diabetes Nursing\n                      and honorarium for journal articles\/work on educational diabetes modules and diabetes educational presentations; co-author of \u201cThe Oxford Handbook of Diabetes Nursing\u201d: second edition; honorarium for presenting\/speaking\/chairing at diabetes educational events, sponsorship for conference attendance under ABPI (declared) AstraZeneca, Boehringer Ingelheim, Lilly Diabetes, Abbott, Novo Nordisk, Sanofi, MyLan, Dexcom, Menarini, Roche and Daiichi Sankyo; advisory board participation for Abbott, Lilly Diabetes, Sanofi, Menarini and Roche. Dipesh Patel: honoraria from consultancy work, clinical trials or education: AstraZeneca, Boehringer Ingelheim, GLG, Lilly, Medpace, Menarini and Novo Nordisk. Samuel Seidu: speaker honoraria from AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, MSD, Abbott, Novo Nordisk, SB Communications, OmniaMed Communications, Roche, Napp Pharmaceuticals, NB Medical and Amgen; advisory board honoraria from AstraZeneca, Lilly, Boehringer Ingelheim, Janssen, Abbott, MSD, Novo Nordisk, Takeda and Sanofi; educational grants from Boehringer Ingelheim, Lilly, Novo Nordisk and Takeda and conference registration; subsistence from Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, Abbott and Takeda. Adie Viljoen: lecturing honoraria for education, conduction of clinical research trials, advisory consultation and\/or travel support funding to attend education events: Amgen, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Kailera, Menarini, New Amsterdam, Novartis, Novo Nordisk, Sanofi and Ultragenyx. David C. Wheeler: led or served on trials committees funded by AstraZeneca, Bayer, Alnylam\/Roche, CSL-Vifor, Inversage\/Novo Nordisk and Tricida. leadership of or service on data safety monitoring boards funded by Aion, Dimerix, Eledon, Galderma, Janssen, CSL-Vifor, Pathaly, ProKidney, Sana, Senya, Synthekine, Takeda and Vertex. Received honoraria for talks and\/or consultancy from AstraZeneca, Astellas, Bayer, Boehringer Ingelheim, Emerald Clinical (formally George Clinical), Glaxo Smith Kline, HighTide, KDIGO, Mineralys, PureSpring and Silence. John P.H. Wilding: consultancy\/advisory board work for the pharmaceutical industry contracted via the University of Liverpool (no personal payment): Alnylam, Amgen, AstraZeneca, Boehringer Ingelheim, Cytoki, Kailera, Lilly, Menarini, Novo Nordisk, Pfizer, Prosciento, Response Pharmaceuticals, Rhythm Pharmaceuticals, Saniona and Shionogi; funding for clinical trials: Amgen, AstraZeneca, Lilly and Novo Nordisk; personal honoraria\/lecture fees: Abbvie, AstraZeneca, Boehringer Ingelheim, Medscape, Novo Nordisk and Menarini.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not involve any new studies of human or animal subjects. Some authors were involved in studies discussed within the paper that included human subjects, all of which complied with the tenets of the Declaration of Helsinki and used protocols that had been approved by relevant institutional review boards\/ethics committees and included patients who had provided written informed consent.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}